The boredom is the interesting part, honestly, because it means the hard question got quietly swapped for an easier one. “How many vials” is a logistics problem and you’ve solved it. “What’s in vial number six when you finally get to it in month five” is a chemistry problem, and that one doesn’t sit still while you wait. A couple of distinctions worth holding onto, because the published stability data answers a slightly different question than the one a stockpiler is actually asking. The within-vial clock (the 4-ish weeks once you’ve reconstituted and started puncturing) is well-trodden ground. The stockpile clock is the other one: sealed or lyophilised product sitting months ahead in a home fridge. Those are not the same conversation, and the bracketing data people quote tends to be from the first. What I’d gently push back on is the min/max instinct, the “my fridge stays between 2 and 8 so I’m fine” reasoning. Deamidation and oxidation don’t care about the extremes, they integrate over the whole storage history. The frame that actually fits is mean kinetic temperature: every hour the vial spent warm (the courier’s porch, the eight hours in transit, the door shelf that cycles every time someone reaches for the milk) gets added to the running total and it does not reset when the vial goes back cold. A day-of-fill COA tells you almost nothing about that. It’s a snapshot of t=0, and you’re asking about t=five months. The other thing, and this is where compounded differs from branded: the kinetic stability numbers people reassure themselves with were generated on a specific formulation, specific excipients, specific buffer. A compounded vial with different buffering isn’t covered by that paper, however confidently it gets cited. The transfer is the weak link, not the storage. None of this is a reason to panic about a stash. It’s a reason to think about storage history rather than headcount. Back of the fridge, not the door. Note the courier excursions if you can. And know that a slow potency drift in the vials you open last is exactly the kind of signal that gets misread later as tolerance, when it’s really the molecule aging out from under you. eta: lyophilised holds up far better than reconstituted for the long-ahead vials, fwiw, if you have the choice at fill.
the “misread later as tolerance” line is the part I’d underline twice, because that’s the exact failure mode I’ve actually watched happen in my own data. I traced an 8 mg/dL CGM drift over two weeks back to prep inconsistency rather than the molecule aging, but the troubleshoot order is the same problem either way: if the only variable you logged is “weeks on dose,” a slow potency loss in the back-of-the-stash vials reads as habituation and the obvious move is to titrate up, which is exactly wrong if the real issue is the vial doing less than it did at fill. the non-linearity is the tell, and it’s why MKT is the right frame over min/max. a drift that’s proportional to vial age is at least predictable. what actually bit me wasn’t proportional, which is what you’d expect if storage history (one bad courier excursion, one week on the door shelf) is doing the work rather than simple first-order decay integrating cleanly over time. the practical wrinkle on top of all this: the field you’d want to log per vial (finished-vial potency for that specific lot, late not just at t=0) is the one the pharmacy won’t hand you, so what you can actually capture is fill date, source, and storage notes, and you have to be honest that those are proxies. tagging the vial in my tracker is the only reason I can line a CGM shift up against “oh, that’s the lot that sat in the warm box,” and the weekly trend summary is what surfaces the drift before I’d otherwise notice it as a vague off week. someone posted recently about treating the COA as a floor not a ceiling and this is the same wall from the storage side: a day-of-fill cert can’t speak to t=five-months no matter how good the number was at fill. lyophilised-if-you-can-get-it is the right call, fwiw.
the “non-linear is the tell” bit is the part i’d hold onto, because first-order decay is the wrong null in the first place. aggregation-prone peptides run sigmoidal, a lag phase while nuclei form then a steeper drop once fibrillation gets going, so a drift that isn’t proportional to vial age is the expected shape even before you layer a bad courier excursion on top. proxies stacked on proxies, but fill date plus storage notes is genuinely the most you can back out after the fact.
Your point about potency drift being misread as tolerance is the whole game. People will chase a complex